MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
Summary
Merck & Co. ($MRK) secures a $2.4B indefinite delivery/indefinite quantity contract from the CDC for the Vaccines for Children program for FY25, representing about 4% of its annual revenue. This award reinforces Merck's dominant position in pediatric vaccines and provides stable, government-backed revenue.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Merck's $2.4B CDC vaccine contract is a routine renewal, not a surprise catalyst.
- 2.The contract represents ~4% of Merck's annual revenue, providing stable cash flow.
- 3.No direct legislative connection; funding comes from annual appropriations.
Market Implications
The contract reinforces Merck's position in the pediatric vaccine market, but given its size relative to total revenue, the impact on $MRK's stock is likely muted. Investors should view this as a steady, low-risk revenue contributor rather than a growth catalyst. Supply chain partners like $GLW and $TMO may see minor indirect benefits, but the effect is diffuse.
Full Analysis
The Department of Health and Human Services, through the Centers for Disease Control and Prevention, awarded Merck Sharp & Dohme LLC a $2.4B contract for the Vaccines for Children program for fiscal year 2025. This is a routine renewal of a longstanding federal program that provides vaccines to children who might otherwise not be vaccinated. Merck Sharp & Dohme is a direct subsidiary of Merck & Co., Inc., a global pharmaceutical giant. With Merck's annual revenue of $60.1B, this contract accounts for roughly 4% of revenue—meaningful but not transformative. The contract is structured as an indefinite delivery/indefinite quantity, meaning the government will order vaccines as needed up to the ceiling amount. No specific legislation directly authorizes this contract; it is funded through annual appropriations for the CDC's immunization programs. Supply chain beneficiaries include vaccine component suppliers such as Corning ($GLW) for glass vials and Thermo Fisher Scientific ($TMO) for cold chain logistics, though these are diversified companies. Historically, Merck has consistently won these contracts, and the stock tends to see modest, sustained support from such predictable government revenue rather than sharp price movements.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Contract Details
Recipient
MERCK SHARP & DOHME LLC
Award Amount
$2,407,704,840
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Disease Control and Prevention
Contract Type
INDEFINITE DELIVERY / INDEFINITE QUANTITY
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →